Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2002
10/10/2002US20020146453 For sustained release; therapy
10/10/2002US20020146450 Liposome-entrapped topoisomerase inhibitors
10/10/2002US20020146439 For therapy of alopecia; cosmetics
10/10/2002US20020146428 Preventing, inhibiting or enhancing binding between pilus subunit and periplasmic molecular chaperone in pilus-forming bacteria, periplasmic molecular chaperone being one that binds pilus subunits during transport of subunits
10/10/2002US20020146424 Polyphenolics for enhancing endothelial cell-mediated fibrinolysis
10/10/2002US20020146421 Diagnosis and treatment of malignant neoplasms
10/10/2002US20020146411 Anticoagulant agents useful in treatment of thrombosis
10/10/2002US20020146400 For threapy of atherosclerotic cardiovascular disease
10/10/2002US20020146397 Unblocking immunization at a regional lymph node by: promoting differentiation and maturation of immature dendritic cells in a regional lymph node and; allowing presentation by resulting mature dendritic cells of antigen to T-cells
10/10/2002US20020146391 For diagnosis and therapy of susceptibility to atopic allergy, asthma
10/10/2002US20020146390 Therapy of sepsis and adult respiratory distress syndrome using chemokine or biologically active fragment thereof, alone or in conjunction with an anti-infective agent
10/10/2002US20020146386 In vivo use of water absorbent polymers
10/10/2002US20020146384 Exhibiting constant release rate and delayed release profiles
10/10/2002US20020146374 For therapy of candidiasis
10/10/2002US20020146373 Administering to the respiratory system of a patient or animal hormone aerodynamically light particles, wherein particles are delivered and deposited to patient's or animal's lungs and hormone is released in patient's or animal's blood stream
10/10/2002US20020146372 Obtaining aerosolizable topical insulin and obtaing short-acting oral hypoglycemic agent having aduration of action shorter than long-acting oral hypoglycemic agents; utilizing insulin and ingesting oral hypoglycemic agent
10/10/2002US20020144946 Special amino acid mixture suitable for dialysis solution for hemodialysis
10/10/2002DE10151148A1 Dietetic or pharmaceutical composition for increasing cellular glutathione levels, especially for combating deficient hepatic function, comprising cysteine, glutathione biosynthesis promoter and e.g. lignan
10/10/2002DE10117676A1 Pesticidal composition, useful for controlling fleas and ticks on animals, contains permethrin and imidacloprid, in N-methylpyrrolidone
10/10/2002DE10117615A1 Verwendung von Nucleosiden, Nucleobasen und deren Derivaten zur verbesserten Gewinnung von adulten Stammzellen Use of nucleosides, nucleobases and their derivatives for improved recovery of adult stem cells
10/10/2002DE10117441A1 1-Indolylderivate, deren Verwendung zur Herstellung von Arzneimitteln, ein Verfahren zur Herstellung der 1-Indolylderivate sowie 1-Indolylderivate enthaltende pharmzeutische Präparate 1-indolyl derivatives, to their use for the preparation of medicaments, a process for preparing the 1-indolyl and 1-indolyl derivatives containing preparations pharmzeutische
10/10/2002DE10117204A1 In 6-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel In the 6-position substituted indolinones, their preparation and their use as medicaments
10/10/2002DE10117183A1 Verwendung von substituierten Imidazo[1,2-a]-pyridinverbindungen als Arzneimittel Use of substituted imidazo [1,2-a] -pyridinverbindungen as medicaments
10/10/2002DE10116978A1 Kappa-Opiatagonisten für die Behandlung von Erkrankungen der Blase Kappa-opiate agonist for the treatment of diseases of the bladder
10/10/2002DE10116768A1 Hypoglycemic medicaments useful for treating type II diabetes contain new or known N-aroyl-N'-phenyl-urea derivatives which are glycogen phosphorylase a inhibitors
10/10/2002DE10116589A1 Use of creatine for reducing oxidative stress e.g. for treating aging, neurodegeneration and cancers
10/10/2002DE10115922A1 Cyclisch substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung Cyclic substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and their use
10/10/2002DE10115840A1 Retinylcarbonate in Kosmetika und Dermatika Retinylcarbonate in cosmetics and skin
10/10/2002DE10115668A1 Agent for treating stroke, blood flow disorders and accumulation of blood in tissues, comprises kinin B1 receptor stimulant, e.g. interleukin-1beta, des-(Arg-9)-bradykinin or captopril
10/10/2002DE10115073A1 Verwendung von Inhibitoren von IKK-ß und Verfahren zum Auffinden solcher Inhibitoren Use of inhibitors of IKK-ß and methods for finding such inhibitors
10/10/2002DE10114775A1 2-Mercapto-4,5-diarylimidazolderivate und ihre Verwendung in der Pharmazie 2-mercapto-4,5-diarylimidazolderivate and their use in the pharmaceutical
10/10/2002DE10114247A1 Antibiotikum-/Antibiotika-Polymer-Kombination Antibiotic / polymer combination
10/10/2002DE10111165A1 Verwendung von Hyaluronsäure-Uroniden zur Behandlung von entzündlichen Vorgängen Use of hyaluronic acid for treating inflammatory processes Uroniden
10/10/2002CA2455915A1 Methods and compositions for using mhc class ii invariant chain polypeptide as a receptor for macrophage migration inhibitory factor
10/10/2002CA2452152A1 Use of cyclopamine in the treatment of psoriasis
10/10/2002CA2445489A1 Metronidazole pledgets
10/10/2002CA2443128A1 Transdermal delivery of pergolide
10/10/2002CA2442798A1 Antioxidant nitroxides and nitrones as therapeutic agents
10/10/2002CA2442775A1 New polynucleotides and polypeptides of the ifn alpha-21 gene
10/10/2002CA2442730A1 Irrigating fluid
10/10/2002CA2442692A1 Bone metabolism improving agents
10/10/2002CA2442691A1 Enteric ketoacid salts and amino acids and their use for preparing medicines
10/10/2002CA2442654A1 Probes, systems, and methods for drug discovery
10/10/2002CA2442619A1 Cancer-testis antigens
10/10/2002CA2442532A1 Colloidal suspension of nanoparticles based on an amphiphilic copolymer
10/10/2002CA2442525A1 Cyclopropylindole derivatives as selective serotonin reuptake inhibitors
10/10/2002CA2442484A1 Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
10/10/2002CA2442482A1 Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases
10/10/2002CA2442481A1 3-heterocyclylpropanohydroxamic acid as procollagen c-proteinase inhibitors
10/10/2002CA2442476A1 Pyridazinone aldose reductase inhibitors
10/10/2002CA2442472A1 Therapeutic agent for bladder irritative symptoms associated with benign prostatic hyperplasia
10/10/2002CA2442468A1 Therapeutic agent for bladder hypersensitivity
10/10/2002CA2442463A1 Therapeutic agent for overactive bladder
10/10/2002CA2442457A1 Carbon monoxide generating compounds for treatment of vascular, inflammatory and immune disorders
10/10/2002CA2442455A1 A method of treating proliferative diseases using eg5 inhibitors
10/10/2002CA2442452A1 Agent for the treatment of bladder irritative symptoms accompanied by benign prostatic hyperplasia
10/10/2002CA2442437A1 Agent for the treatment of overactive bladder
10/10/2002CA2442428A1 Novel tyrosine kinase inhibitors
10/10/2002CA2442410A1 Duloxetine for treatment of hot flashes
10/10/2002CA2442370A1 Methods for increasing serotonin levels by administering (-)-hydroxycitric acid
10/10/2002CA2442365A1 Premixed amiodarone parenteral solution and method for making the same
10/10/2002CA2442354A1 New pyrimidine-2,4,6-trione derivatives, processes for their production and pharmaceutical agents containing these compounds
10/10/2002CA2442330A1 Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
10/10/2002CA2442329A1 Imidazo-triazine derivatives as pde 5 inhibitors
10/10/2002CA2442328A1 Therapeutic combinations for cardiovascular and inflammatory indications
10/10/2002CA2442263A1 Substituted 2-carba-3,5-dicyano-4-aryl-6-aminopyridines and the use of the same as selective ligands of the adenosine receptor
10/10/2002CA2442150A1 Sapogenin derivatives, their synthesis and use, and methods based upon their use
10/10/2002CA2442146A1 Formulations comprising entrapped active ingredients and uses thereof
10/10/2002CA2442106A1 Conjugated unsaturated glyceride mixtures and a method for producing the same
10/10/2002CA2441778A1 Aminopiperidine derivatives as modulators of chemokine receptor activity
10/10/2002CA2441654A1 Cytoskeleton-associated proteins
10/10/2002CA2441335A1 Synergistic combinations of retinoid receptor ligands and selected cytotoxic agents for treatment of cancer
10/10/2002CA2441252A1 Estrogen replacement therapy
10/10/2002CA2441077A1 Substituted carbazoles as inhibitors of spla2
10/10/2002CA2440534A1 Antitumor methods and compositions comprising sesquiterpene derivatives
10/10/2002CA2440430A1 Low glycemic response compositions
10/10/2002CA2440249A1 Methods for the production of 3-o-deactivated-4'-monophosphoryl lipid a (3d-mla)
10/10/2002CA2440228A1 Inhibitors of cyclin dependent kinases as anti-cancer agent
10/10/2002CA2440108A1 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
10/10/2002CA2439842A1 Gaba-receptor modulators for the treatment of neurodegenerative diseases of the eye
10/10/2002CA2438272A1 Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same
10/10/2002CA2438210A1 Steroid compounds, use of these compounds for the preparation of meiosis-regulating medicaments and method for the preparation of these compounds
10/10/2002CA2437789A1 Topical composition comprising an antifungal
10/10/2002CA2437113A1 N-phenpropylcyclopentyl-substituted glutaramide derivatives as nep inhibitors for fsad
10/10/2002CA2435390A1 Compositions, methods and apparatuses for singlet oxygen delivery
10/10/2002CA2430684A1 Micromonospora echinospora genes encoding for biosynthesis of calicheamicin and self-resistance thereto
10/10/2002CA2406832A1 Preventives/remedies for alzheimer's disease
10/09/2002WO2001079168A1 Nitrogenous compounds and antiviral drugs containing the same
10/09/2002EP1247810A1 Novel benzotriazoles anti-inflammatory compounds
10/09/2002EP1247809A2 Triazine compounds useful as sorbitol dehydrogenase inhibitors
10/09/2002EP1247804A1 Pyrimidine-thioalkyl and alkylether compounds
10/09/2002EP1247803A2 Indolinone compounds suitable for modulation of protein kinases
10/09/2002EP1247533A2 Combination treatment of multiple sclerosis (MS), other demyelinating conditions and peripheral neuropathy, especially painful neuropathies and diabetic neuropathy
10/09/2002EP1247526A1 Perfusion liquid preparations for ophthalmic operations
10/09/2002EP1247525A1 Use of a monosaccharide in the manufacture of a medicament against acute mountain sickness
10/09/2002EP1247524A1 Composition comprising taurolidine and/or taurultam for the treatment of cancer
10/09/2002EP1247523A1 Essential fatty acids in the prevention of cardiovascular events
10/09/2002EP1247521A1 Use of biguanide and pyrimidine derivatives for the preparation of a topical skin care composition
10/09/2002EP1246946A2 Compositions and methods for the discovery and selection of biological information
10/09/2002EP1246940A2 Chemotherapeutant screening method
1 ... 5685 5686 5687 5688 5689 5690 5691 5692 5693 5694 5695 5696 5697 5698 5699 5700 5701 5702 5703 5704 5705 ... 7860